Price: $184.2
· 1 day: -1.37% · 5 days: -2.54% · 1 month: +16.34% · YTD: +0.18%
As of 2026-11-11 17:09 UTC.
52-week range: $153.41 – $212.71 (currently at 52% of the range).
AZN is in an uptrend, momentum firm. $187.12 is the level overhead; $183.01 the first support below.
4 of 6 technical checks lean bullish.
| Trend | Uptrend · above 50-day & 200-day |
|---|---|
| Momentum | RSI 61.7 · MACD bullish |
| Trend strength | ADX 26.4 · strong trend |
| Location | +9.7% vs 50-day MA |
| 52-week range | -12% from high · +18% from low |
| Volatility | ATR 4.89 · ~2.7%/day |
| Level | Type | Distance |
|---|---|---|
| $187.12 (resistance) | swing zone | 1.59% |
| $190.43 (resistance) | swing zone | 3.38% |
| $200.0 (resistance) | round | 8.58% |
| $183.01 (support) | swing zone | -0.65% |
| $180.19 (support) | sma 200 | -2.18% |
| $179.25 (support) | swing zone | -2.69% |
| RSI (14) | 61.68 | MACD | 6.2196 |
|---|---|---|---|
| ADX (14) | 26.4 | ATR (14) | 4.89 |
| 50-day average | $167.93 | 200-day average | $180.19 |
Next earnings: 2026-10-30. AZN earnings date, time and past reactions.
Report of 2026-11-11.
AstraZeneca plc closed at $186.76 on November 10, holding above its swing‑zone support of $183.01 while the daily trend remains in step with a weekly uptrend. The stock has outperformed the S&P 500 by 13.7% over the past 50 days and led the healthcare sector XLV by 2.8% in the same span. With the price still below the 52‑week high but well above its 40‑week average, the balance of evidence points to a bullish short‑term outlook.
The recent move stems from a modest pull‑back after a peak of $189.39 on November 9, a 1.4% decline that left the stock near its recent swing‑zone resistance at $187.86. Volume was 45.9% below its 20‑day average, suggesting limited selling pressure and a market that has already priced in the short‑term dip. The broader market has been weaker, with the S&P 500 down 0.37% on the day and –0.59% over five days, while the healthcare sector ETF XLV rose 0.29% daily and 2.64% over five days. The stock’s 5‑day gain of 1.57% therefore reflects a net outperformance of roughly 1.1% versus its sector.
Analysts remain optimistic, with twelve forecasts averaging a $208.1 target – roughly 10% above the current price. The consensus rating is “buy,” and the spread between the low and high targets ($158‑$240) underscores a wide upside potential. The valuation gap is modest; the price sits about 10% below the mean target, leaving room for the market to move higher without a dramatic shift in expectations.
Debate among commentators centers on two points. One side argues that the stock’s RSI of 66 and its proximity to the swing‑zone resistance suggest a near‑term ceiling, warning that a failure to break $187.86 on volume could trigger a test of the $180.23 200‑day SMA. The opposing view notes that the long‑term trend remains intact – the price is above its 40‑week average and the daily trend aligns with the weekly uptrend – and that the relative strength versus both the market and sector indicates continued buying pressure.
There is no specific news catalyst in the past 24 hours; the earnings report dated October 30, 2026, has already been digested, and no new developments have emerged. Consequently, the price action reflects pure technical dynamics and the ongoing sector rotation into healthcare.
On the long‑term horizon the thesis remains solid. The stock sits above its 40‑week average, the 200‑day SMA at $180.23 provides a robust support floor, and the 52‑week range shows the price only 10.9% below the high of $209.48, leaving ample room for a continuation of the uptrend. The weekly trend is still upward, and the daily price is comfortably above the 50‑day SMA of $167.5.
Looking ahead to the next two‑to‑six weeks, the balance of evidence leans positive with high conviction. The assessment calls for a bullish stance, three of four conviction points satisfied, and the breakout math meets a 3‑to‑1 reward‑to‑risk ratio. The strongest counter‑argument is the recent dip in volume – down 45.9% versus the 20‑day average – which could signal waning participation if buyers do not step in at the swing‑zone resistance. However, the price’s hold above $183.01 and the alignment of daily and weekly trends keep that risk from outweighing the upside case.
The structure holds above the swing‑zone support at $183.01; a break below this level would be the first crack in the pattern, while a move under $180.23 – the 200‑day SMA – would signal the end of the current uptrend. The key breakout trigger is a daily close above $187.86 on volume exceeding the 20‑day average. If that occurs, the math projects a first target at $192.26, a swing‑zone‑based level offering a reward‑to‑risk of 0.7, and a longer‑run target at $209.48, the 52‑week high, delivering a reward‑to‑risk of 3.5. The stop is placed at $181.75, derived from the swing‑zone low of $183.01 less a quarter of the 14‑day ATR ($5.05), providing a tight risk margin.
A weekly close below the 200‑day SMA at $180.23 would alter the outlook, as the picture‑changing rule ties trend termination to that level. A material earnings surprise – either a significant beat or miss on the upcoming quarterly results – would also shift the narrative, potentially redefining support and resistance zones.
Interactive AZN chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs